Vision Loss Clinical Trials

A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 69 clinical trials
A Prospective Randomized Double-Blind Placebo-Controlled Crossover Study to Evaluate the Clinical Utility of the Vascular Health Profile Diagnostics Assay (VHP) in Assessment of Response to Administration of a HMG-CoA reductase inhibitor (statin) as Primary Prevention in Patients with Asymptomatic Atherosclerosis

This is a prospective, single-center, randomized double-blind, placebo-controlled, crossover study conducted in the United States (US). Patients will be randomized into two treatment sequences (treatment A in period 1, followed by treatment B in period 2, or treatment B in period 1, followed by treatment A in period 2).

  • 0 views
  • 19 Feb, 2024
  • 1 location
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase III multi-center double-blind randomized withdrawal study of LCI699 following a 24 week single-arm open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushings disease (PRIME)

The study aims to confirm the long-term efficacy and safety of LCI699 for the treatment of patients with Cushing's disease who have had had surgery that has not been successful, or are not a good surgical candidate, or refuse surgery, and have not received radiation treatment for this condition within …

  • 0 views
  • 19 Feb, 2024
  • 1 location
A randomized double-blind placebo controlled multi-center study to assess the effect of ranolazine on outcomes in subjects with pulmonary hypertension and right ventricular dysfunction accompanied by a comparative study of cellular metabolism in subjects with pulmonary hypertension with and without right ventricular dysfunction

A multi-center study evaluating the effects of ranolazine in subjects with class II/III/IV pulmonary hypertension on stable background therapy and persistent RV dysfunction. Study involves an observational arm and a 26-week treatment arm. At baseline (wk 0), interim (wk 13) and the conclusion of treatment period (wk 26) subjects will …

  • 0 views
  • 19 Feb, 2024
  • 1 location
UPCC 15518 / ANAM-17-21: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

The main purpose of this study is to learn more about how well the experimental drug, anamorelin hydrochloride (HCl), works to prevent weight loss and anorexia in patients with advanced Non-Small Cell Lung Cancer.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A phase 2b double-blind randomised 5-arm vehicle-controlled dose ranging trial to evaluate the efficacy and safety of twice daily topical applications of delgocitinib cream 1 3 8 20 mg/g for 8 weeks in adult subjects with mild to severe atopic dermatitis.

The purpose of this clinical trial is to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects atopic dermatitis (a type of eczema). key eligibility include: Age 18 years and above. Diagnosis of AD …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Effect of Organic Nitrates and Hydralazine on Wave Reflections and Left Ventricular Structure and Function in Heart Failure with Preserved Ejection Fraction

The purpose of this study is to test the effect of prolonged therapy (24 weeks) with isosorbide dinitrate ± hydralazine on arterial wave reflections, exercise capacity, left ventricular (LV) mass/fibrosis and diastolic function in patients with Heart Failure and Preserved Ejection Fraction (HFPEF). This is a double-blind, placebo-controlled pilot randomized …

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Pilot Study to Evaluate the Effect of CT1812 Treatment on A-beta Oligomer Displacement into CSF in Subjects with Mild to Moderate Alzheimer's Disease

Cognition Therapeutics is developing an oral formulation of CT1812 to treat AD and mild cognitive impairment. This is a multi-center, Phase 1b, randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to moderate AD, sponsored by the NIH. The primary purpose of this study is to evaluate target engagement of …

  • 0 views
  • 19 Feb, 2024
  • 1 location
18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimers Disease

BAN2401-G000-301 (Study 301) is an 18-month treatment (Core Study), multicenter, double-blind, placebo-controlled, parallel-group study in subjects with EAD (mild cognitive impairment [MCI] due to AD with intermediate likelihood/Prodromal AD or mild AD dementia) with confirmed amyloid pathology indicated by either positive amyloid load confirmed by amyloid PET assessment or CSF …

  • 0 views
  • 19 Feb, 2024
  • 1 location